Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.

NCT Number	NCT05717764
Lead Sponsor	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions	Recurrent Metastatic Nasopharyngeal Carcinoma
Enrollment	500 participants
Start Date	2023-02
Primary Completion	2026-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2023-02-08